This study analyses how 14 OECD Countries refer to “value” when making decisions on
reimbursement and prices of new medicines. It details the type of outcomes considered, the …

Objectives To characterize at a global level the concept of therapeutic value (TV) and
describe the experience of value-based pricing (VBP) policies in 6 reference countries …

This article argues that the misalignment of private profit-maximizing objectives with public
health needs causes institutional corruption in the pharmaceutical sector and systematically …

How are medicine prices decided upon in European countries? Which challenges do policy
makers face? Which role do reimbursement aspects play in the pricing process? Are there …

Background Many patients even those with health insurance pay out-of-pocket for
medicines. We investigated the availability and prices of essential medicines in the Boston …

This article reports on the involvement of nurses and physicians in improvement work, with a
special focus on the drivers. The purpose was to describe how the nurse and physician …

Abstract The New Public Governance (NPG) paradigm addresses problems of complex and
fragmented policy‐making. Health care is an increasingly complex policy area, and Canada …

Objectives Monetizing health has sparked controversy and has implications for pricing
strategies of emerging health technologies. Medical insurance payers typically set up …

While Canada has a well-established tradition of transparency and accountability for health-
system performance comparisons, few measures of outcomes are reported. In this …

We investigate the impact of pharmaceutical spending and retail sales in major anatomical
therapeutic classes on domestic early-stage innovation. For our analysis, we incorporate …